Survodutide

Survodutide (BI 456906) is a dual glucagon and GLP-1 receptor agonist by Boehringer Ingelheim that synergistically activates both pathways to promote weight loss, enhance hepatic lipid metabolism, and improve insulin sensitivity. In Phase 2 obesity trials, survodutide achieved 18.7% weight loss over 46 weeks, while in MASH studies, 83% of patients achieved resolution of steatohepatitis without worsening fibrosis compared to 18.2% with placebo. The compound has received FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis, with Phase 3 trials currently underway. Its clinical distinction is dual optimization for both obesity and liver disease with favorable tolerability.

10mg